1887

Microbial Genomics logo

Volume 9, Issue 9

Molecular characterization of causing disease among children in Nigeria during the introduction of PCV10 (GSK) Open Access

Abstract

() is a leading vaccine-preventable cause of childhood invasive disease. Nigeria has the second highest pneumococcal disease burden globally, with an estimated ~49 000 child deaths caused by pneumococcal infections each year. Ten-valent pneumococcal conjugate vaccine (GSK; PCV10) was introduced in December 2014 in a phased approach. However, few studies have characterized the disease-causing pneumococci from Nigeria. This study assessed the prevalence of serotypes, antibiotic susceptibility and genomic lineages using whole genome sequencing and identified lineages that could potentially escape PCV10 (GSK). We also investigated the potential differences in pneumococcal lineage features between children with and without sickle cell disease. A collection of 192 disease-causing pneumococcal isolates was obtained from Kano (=189) and Abuja (=3) states, Nigeria, between 1 January 2014 and 31 May 2018. The majority (99 %, 190/192) of specimens were recovered from children aged 5 years or under. Among them, 37 children had confirmed or traits of sickle cell disease. Our findings identified 25 serotypes expressed by 43 Global Pneumococcal Sequence Clusters (GPSCs) and 85 sequence types (STs). The most common serotypes were 14 (18 %, =35), 6B (16 %, =31), 1 (9 %, =17), 5 (9 %, =17) and 6A (9 %, =17); all except serotype 6A are included in PCV10 (GSK). PCV10 (SII; PNEUMOSIL) and PCV13 formulations include serotypes 6A and 19A which would increase the overall coverage from 67 % by PCV10 (GSK) to 78 and 82 %, respectively. The pneumococcal lineages were a mix of globally spreading and unique local lineages. Following the use of PCV10 (GSK), GPSC5 expressing serotype 6A, GPSC10 (19A), GPSC26 (12F and 46) and GPSC627 (9L) are non-vaccine type lineages that could persist and potentially expand under vaccine-selective pressure. Approximately half (52 %, 99/192) of the pneumococcal isolates were resistant to the first-line antibiotic penicillin and 44 % (85/192) were multidrug-resistant. Erythromycin resistance was very low (2 %, 3/192). There was no significant difference in clinical manifestation, serotype prevalence or antibiotic resistance between children with and without traits of or confirmed sickle cell disease. In summary, our findings show that a high percentage of the pneumococcal disease were caused by the serotypes that are covered by currently available vaccines. Given the low prevalence of resistance, macrolide antibiotics, such as erythromycin, should be considered as an option to treat pneumococcal disease in Nigeria. However, appropriate use of macrolide antibiotics should be vigilantly monitored to prevent the potential increase in macrolide resistance.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): genomics , Nigeria , pneumococcal conjugate vaccine and Pneumococci
Funding
This study was supported by the:
  • Wellcome Trust (Award 206194)
    • Principle Award Recipient: StephenD Bentley
  • Wellcome Trust (Award 098051)
    • Principle Award Recipient: StephenD Bentley
  • Bill and Melinda Gates Foundation (Award OPP1034556)
    • Principle Award Recipient: StephenD Bentley
  • Bill and Melinda Gates Foundation (Award OPP1034619)
    • Principle Award Recipient: StephenK Obaro
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.001094
2023-09-15
2024-05-02
Loading full text...

Full text loading...

/deliver/fulltext/mgen/9/9/mgen001094.html?itemId=/content/journal/mgen/10.1099/mgen.0.001094&mimeType=html&fmt=ahah

References

  1. Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health 2018; 6:e744–e757 [View Article] [PubMed]
     [Google Scholar]
  2. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371:1889–1899 [View Article] [PubMed]
     [Google Scholar]
  3. Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U et al. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 2016; 16:703–711 [View Article] [PubMed]
     [Google Scholar]
  4. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis 2018; 18:441–451 [View Article] [PubMed]
     [Google Scholar]
  5. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301–309 [View Article] [PubMed]
     [Google Scholar]
  6. Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A et al. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine 2018; 36:572–577 [View Article] [PubMed]
     [Google Scholar]
  7. Turner P, Leab P, Ly S, Sao S, Miliya T et al. Impact of 13-valent pneumococcal conjugate vaccine on colonization and invasive disease in Cambodian children. Clin Infect Dis 2020; 70:1580–1588 [View Article] [PubMed]
     [Google Scholar]
  8. WHO, World Health Organization WHO | Immunization Country Profile n.d https://apps.who.int/immunization_monitoring/globalsummary/estimates?c=NGA accessed 14 May 2021
    [Google Scholar]
  9. Tagbo BN, Bancroft RE, Fajolu I, Abdulkadir MB, Bashir MF et al. Pediatric bacterial meningitis surveillance in Nigeria from 2010 to 2016, prior to and during the phased introduction of the 10-valent pneumococcal conjugate vaccine. Clin Infect Dis 2019; 69:S81–S88 [View Article] [PubMed]
     [Google Scholar]
  10. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. N Engl J Med 1966; 274:1006–1008 [View Article] [PubMed]
     [Google Scholar]
  11. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381:142–151 [View Article] [PubMed]
     [Google Scholar]
  12. Battersby AJ, Knox-Macaulay HHM, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010; 55:401–406 [View Article] [PubMed]
     [Google Scholar]
  13. Cober MP, Phelps SJ. Penicillin prophylaxis in children with sickle cell disease. J Pediatr Pharmacol Ther 2010; 15:152–159 [PubMed]
     [Google Scholar]
  14. Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev 2004CD003885 [View Article] [PubMed]
     [Google Scholar]
  15. GPS:: Global Pneumococcal Sequencing Project n.d https://www.pneumogen.net/gps/ accessed 5 March 2021
    [Google Scholar]
  16. Obaro SK, Hassan-Hanga F, Olateju EK, Umoru D, Lawson L et al. Salmonella bacteremia among children in central and Northwest Nigeria, 2008-2015. Clin Infect Dis 2015; 61:S325–S331 [View Article] [PubMed]
     [Google Scholar]
  17. Gladstone RA, Lo SW, Lees JA, Croucher NJ, van Tonder AJ et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine 2019; 43:338–346 [View Article] [PubMed]
     [Google Scholar]
  18. Epping L, van Tonder AJ, Gladstone RA, Bentley SD, Page AJ et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom 2018; 4:e000204 [View Article] [PubMed]
     [Google Scholar]
  19. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE et al. Penicillin-binding protein transpeptidase signatures for tracking and predicting β-lactam resistance levels in Streptococcus pneumoniae . mBio 2016; 7:e00756-16 [View Article] [PubMed]
     [Google Scholar]
  20. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE et al. Validation of β-lactam minimum inhibitory concentration predictions for pneumococcal isolates with newly encountered penicillin binding protein (PBP) sequences. BMC Genomics 2017; 18:621 [View Article] [PubMed]
     [Google Scholar]
  21. Metcalf BJ, Gertz RE, Gladstone RA, Walker H, Sherwood LK et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 2016; 22: [View Article] [PubMed]
     [Google Scholar]
  22. Metcalf BJ, Chochua S, Gertz RE, Li Z, Walker H et al. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States. Clin Microbiol Infect 2016; 22:1002 [View Article] [PubMed]
     [Google Scholar]
  23. Sanger_SPN_Scripts-Ref Github. n.d https://github.com/BenJamesMetcalf/Sanger_SPN_Scripts-Ref accessed 27 April 2021
  24. Lees JA, Harris SR, Tonkin-Hill G, Gladstone RA, Lo SW et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res 2019; 29:304–316 [View Article] [PubMed]
     [Google Scholar]
  25. GPS:: Global Pneumococcal Sequencing Project n.d https://www.pneumogen.net/gps/training_command_line.html accessed 27 April 2021
    [Google Scholar]
  26. J. Page A, Taylor B, A. Keane J. Multilocus sequence typing by blast from de novo assemblies against PubMLST. J Open Source Softw 2016; 1:118 [View Article]
     [Google Scholar]
  27. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490 [View Article] [PubMed]
     [Google Scholar]
  28. Cohen J. Statistical Power Analysis for the Behavioral Sciences Academic Press; 2013 [View Article]
     [Google Scholar]
  29. Considerations for pneumococcal conjugate vaccine (PCV) product choice WHO 2021 https://apps.who.int/iris/handle/10665/344915
     [Google Scholar]
  30. Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. J Infect 2018; 77:368–378 [View Article] [PubMed]
     [Google Scholar]
  31. Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2:e31 [View Article] [PubMed]
     [Google Scholar]
  32. Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis 2019; 19:759–769 [View Article] [PubMed]
     [Google Scholar]
  33. Szu SC, Lee CJ, Parke JC, Schiffman G, Henrichsen J et al. Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers. Infect Immun 1982; 35:777–782 [View Article] [PubMed]
     [Google Scholar]
  34. Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428–1433 [View Article] [PubMed]
     [Google Scholar]
  35. Oligbu G, Fallaha M, Pay L, Ladhani S. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. Br J Haematol 2019; 185:743–751 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.001094
Loading
Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK)
M Gen 9, 001094 (2023); https://doi.org/10.1099/mgen.0.001094
/content/journal/mgen/10.1099/mgen.0.001094
/content/journal/mgen/10.1099/mgen.0.001094
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error